Pharmacy · Independent exam preparation
Common Registration Assessment: 2026 Free Preparation Guide Study Guide
Practise urgent referrals, high-risk medicine decisions, professional judgement and multistep calculations for the UK Common Registration Assessment in 2026.
By CertMedbry · Updated 30 October 2026
Learn to distinguish urgent symptoms from routine medicine problems, prevent high-risk dosing errors, communicate safe plans and solve practical pharmacy calculations. This guide selects 60 substantive concepts across the two official domains for the Common Registration Assessment at the point of pharmacist registration. The official framework for sittings in 2026 defines the full assessment scope; this selective guide does not cover every assessable topic.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which assessment and registration level does this guide cover?
The Common Registration Assessment for sittings in 2026 assesses safe and effective pharmacy practice at the point of pharmacist registration in the UK. Passing it is one registration requirement, alongside other specified criteria. It is jointly delivered by the GPhC and Pharmaceutical Society Northern Ireland.
Common Registration Assessment framework: For sittings in 2026
How many questions are there, and how long does each part last?
Part 1 contains 40 numerical-entry pharmacy and healthcare calculations in 120 minutes. Part 2 contains 120 selected-response questions in 150 minutes. Both parts are taken on the same day, with a scheduled break between them.
Common Registration Assessment specification and permitted items for sittings in 2026 · Common Registration Assessment regulations for sittings in 2026
Which question styles does the official assessment use?
Part 1 requires numerical free-entry answers. Part 2 comprises 90 five-option single-best-answer questions and 15 extended-matching sets, each containing two questions with eight shared options. The 20 four-option questions here are independent learning drills, not a reproduction of the official assessment format.
Common Registration Assessment specification and permitted items for sittings in 2026
Are there unscored questions, negative marking or a fixed passing percentage?
The specification awards one mark for each correct answer and deducts no marks for incorrect answers or omissions. The official documents do not identify a separate unscored or pretest allocation. Pass marks vary between sittings to reflect question difficulty. Candidates must meet the pass mark in each part in the same sitting; stronger performance in one part cannot compensate for the other.
Common Registration Assessment specification and permitted items for sittings in 2026 · Common Registration Assessment framework: For sittings in 2026
How is the assessment delivered, and is it adaptive?
It is computer-based and delivered in Surpass-partnered UK test centres; a paper assessment is unavailable. The documents specify fixed part lengths and randomised question order, with extended-matching sets kept together. They do not describe an adaptive testing algorithm.
Common Registration Assessment specification and permitted items for sittings in 2026
Which blueprint version and domain weights apply?
This guide uses the official framework for sittings in 2026 hosted in December 2025. That hosting month is not a verified day-specific revision date. The domains are Person-centred care and collaboration and Professional practice. No domain percentages are published. Cardiovascular is the most frequently assessed clinical area, but clinical areas have no fixed question minima or maxima. The guide, questions and cards use an editorial balance across both domains without claiming official percentages.
Common Registration Assessment framework: For sittings in 2026
Do MPharm, OSPAP and other eligible routes take different assessments?
The regulations cover eligible MPharm graduates, OSPAP graduates and EEA-qualified pharmacists required to take the assessment. The framework states that its format and content are the same for all trainee pharmacists in 2026, irrespective of their preceding route. Independent prescribing learning outcome 37, the act of prescribing, is assessed through the relevant training arrangements rather than the CRA.
Common Registration Assessment regulations for sittings in 2026 · Common Registration Assessment framework: For sittings in 2026
Which references and calculators are available?
Selected questions provide resources through the platform's PDF viewer. Candidates cannot bring their own reference texts, and common guidelines should be known. An approved physical calculator or the provided on-screen calculator may be used under the specification. Laboratory reference ranges are supplied; normal ranges for common physiological parameters are not.
Common Registration Assessment specification and permitted items for sittings in 2026 · Common Registration Assessment framework: For sittings in 2026
Which calculation categories must preparation include?
Every Part 1 includes at least one question on each of nine categories: concentrations, dilutions, displacement volumes, dose and dosage regimens, infusion rates, medical statistics, pharmacoeconomics, pharmacokinetics and quantities to supply. Questions are multistep and may require conversions, resource interpretation and appropriate rounding. Simple everyday formulae should be known; more complex formulae are provided.
Common Registration Assessment framework: For sittings in 2026
The Common Registration Assessment is jointly delivered by the GPhC and Pharmaceutical Society Northern Ireland across the UK. This independent learning guide uses its current official identity; the workbook's GPhC Registration Assessment label refers to the same assessment. Professional-standards examples specifically involving GPhC practice are set in Great Britain. Worked statutory emergency-supply examples are set in England.
Outline used: Common Registration Assessment framework: For sittings in 2026, using the opened official December 2025-hosted version. The workbook label 'General Pharmaceutical Council (GPhC) Registration Assessment' maps to this jointly delivered assessment; its assigned slug is preserved. The document specifies 2026 sittings but does not give a separate day-specific revision date.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Person-centred care and collaborationnot stated
1.Why does an NSAID request matter during DOAC treatment?
An NSAID can increase bleeding risk when combined with a direct oral anticoagulant. The decision therefore depends on the existing anticoagulant and the proposed additional medicine, even when the NSAID is available without prescription. Establish what the person already takes, why analgesia is needed and whether bleeding symptoms are present. Avoid treating non-prescription availability as evidence of suitability; the interaction requires an individual assessment and a safer pain-management plan.
Apply it
A person collecting apixaban asks for ibuprofen for new knee pain. Identify the increased bleeding risk, assess the pain and any bleeding symptoms, and agree an appropriate alternative or clinical review rather than supplying automatically.
Common pitfall: Checking only for duplicate analgesics misses the important interaction. Buying a medicine without a prescription does not remove its potential to increase anticoagulant-related harm.
NHS SPS: Managing interactions with direct oral anticoagulants
2.What should an anticoagulant alert card communicate?
An anticoagulant alert card tells healthcare professionals that the person takes a medicine such as apixaban that affects clotting. It supports safer decisions during dental care, procedures, emergencies and new prescribing. Counselling should connect carrying the card with telling professionals about treatment, rather than treating the card as a substitute for discussion. Confirm that the person recognises the medicine's purpose and knows to disclose it before additional treatment is planned.
Apply it
A person starting apixaban says their dentist already knows their usual medicines. Explain that they should still carry the alert card and tell the dental team about apixaban whenever treatment is being considered.
Common pitfall: An alert card does not authorise the patient to interrupt anticoagulation before a procedure. Changes require an individual plan from the treating healthcare team.
3.Why can a raised clinic blood pressure need confirmation?
Blood pressure varies, and a clinic measurement may differ from readings obtained during ordinary daily life. A raised clinic reading commonly leads to ambulatory or home monitoring to help establish whether blood pressure is persistently high. Interpret the measurement in its setting and alongside symptoms rather than diagnosing hypertension from one isolated value. Confirmation is a diagnostic step; it does not justify delaying urgent assessment when the person also has concerning acute symptoms.
Apply it
An asymptomatic adult reports a clinic reading of 148/94 mmHg and asks whether this proves hypertension. Explain that further assessment, often including ambulatory or home readings, helps determine whether the elevation persists outside the clinic.
Common pitfall: Calling every raised clinic reading established hypertension ignores measurement variation. Conversely, describing the reading as anxiety without arranging appropriate follow-up also leaves the finding unresolved.
4.Which threshold helps interpret home blood pressure?
The NHS describes high blood pressure as usually 140/90 mmHg or higher when measured by a healthcare professional, or an average of 135/85 mmHg or higher at home. The distinction matters because the setting changes the threshold used to interpret results. Use a representative average rather than selecting the most reassuring individual reading. A result below the clinic threshold can still merit review when it exceeds the home threshold.
Apply it
A person's home monitoring average is 138/87 mmHg. They dismiss it because it is below 140/90 mmHg. Explain that the usual home threshold is lower and that this average warrants discussion with their healthcare professional.
Common pitfall: Applying the clinic threshold to home averages can falsely reassure someone. A single home reading is also less informative than the appropriately collected monitoring average.
5.When should symptoms suggest lithium toxicity?
Lithium toxicity should be considered when gastrointestinal symptoms occur with neurological changes such as coarse tremor, poor coordination, confusion or unsteadiness. Toxicity can occur even when a measured concentration appears within the usual range, so symptoms remain important. SPS advises withholding lithium when toxicity is suspected, obtaining an urgent lithium level and urea and electrolytes, and seeking specialist advice. The immediate decision is driven by the clinical picture rather than a routine monitoring schedule.
Apply it
A lithium-treated patient develops diarrhoea, marked tremor and difficulty walking after becoming unwell. Treat this as suspected toxicity: withhold lithium and arrange urgent assessment, lithium measurement and renal/electrolyte testing rather than waiting for routine monitoring.
Common pitfall: A previously satisfactory lithium result cannot exclude today's toxicity. Explaining new unsteadiness as an ordinary adverse effect risks delaying assessment of a potentially serious presentation.
6.How does lithium sample timing affect interpretation?
Routine lithium monitoring commonly uses a sample taken 12 hours after the last dose. For usual once-nightly treatment, this means the following morning, rather than immediately before the next evening dose. A 12-hour sample may coincide with the next dose on some divided regimens. Record the preparation, regimen, last-dose time and actual sampling interval, and interpret the result against the corresponding monitoring target. Product instructions can distinguish 12-hour and 24-hour targets; these must not be interchanged. Suspected toxicity requires urgent investigation without waiting for routine sample timing.
Apply it
A patient takes lithium at 10 pm. A routine 12-hour sample is due at 10 am the next morning; an 8 am sample represents ten hours. Document the actual interval and clarify interpretation before changing the dose. Do not move the next evening dose to the morning to create a pre-dose sample.
Common pitfall: Calling every lithium monitoring result a pre-dose trough can confuse once-nightly treatment with divided dosing. Timing and the selected target must correspond.
How and when to take lithium - NHS · NHS SPS: Lithium monitoring · Priadel 400 mg prolonged-release tablets - Summary of Product Characteristics (SmPC) - (emc) | 13163
7.Why are Parkinson's medicines time critical?
People with Parkinson's disease may depend on individually timed medicines to maintain symptom control. Delayed or omitted doses can cause significant deterioration, so their established schedule matters when care settings or administration methods change. Obtain the actual regimen rather than fitting treatment automatically into standard medicine rounds. If swallowing becomes difficult, preserve timely treatment by arranging an appropriate formulation plan; the problem requires active coordination rather than simply leaving doses off the chart.
Apply it
A patient admitted to hospital normally takes Parkinson's medicines at specific times that differ from ward rounds. Communicate the established schedule promptly and ensure the administration plan preserves those times while any swallowing concerns are assessed.
Common pitfall: A correct total daily dose does not guarantee safe treatment if doses are substantially delayed. Standard administration times may fail to meet an individual's time-critical needs.
NHS SPS: Parkinson's disease medicines in swallowing difficulties
8.How should Parkinson's treatment change when swallowing becomes difficult?
Immediate-release co-careldopa tablets, including Sinemet, can be dispersed in water off-label. Modified-release co-careldopa tablets must not be crushed. If the assessed swallow permits water, dispersing the existing immediate-release dose can preserve its usual timing while specialist review is arranged. Modified-release treatment needs an appropriate conversion, rather than manipulation or an assumed milligram-for-milligram substitution. Monitor tremor, stiffness, discomfort and cognition after administration changes. Carers or care-home staff need a prescriber's written direction for off-label administration, recorded in the MAR chart and care plan.
Apply it
A patient taking immediate-release Sinemet can safely swallow water but cannot manage tablets. Use the authorised off-label dispersion instructions to give the full dose at its established time while arranging specialist review. The same approach must not be applied to Sinemet CR.
Common pitfall: Release type determines suitability. Waiting for specialist review must not become an avoidable missed dose when a suitable administration method is available.
NHS SPS: Parkinson's disease medicines in swallowing difficulties
9.Why does near-normal glucose not exclude SGLT2-associated ketoacidosis?
SGLT2 inhibitor-associated diabetic ketoacidosis may present with only moderately raised or near-normal blood glucose. Nausea, vomiting, abdominal pain, rapid or deep breathing, unusual fatigue or sleepiness therefore require attention even when glucose seems reassuring. MHRA advice is to test for raised ketones when symptoms suggest ketoacidosis and discontinue the SGLT2 inhibitor immediately if ketoacidosis is suspected or diagnosed. Recognition depends on the symptom pattern and medicine history, not glucose alone.
Apply it
A person taking an SGLT2 inhibitor has vomiting, abdominal pain and deep breathing but reports a glucose reading close to their usual range. Arrange immediate medical assessment for possible ketoacidosis rather than recommending home observation based on glucose.
Common pitfall: Using marked hyperglycaemia as a required diagnostic cue can miss this presentation. A reassuring glucose value does not neutralise compatible symptoms in an SGLT2-treated patient.
MHRA: SGLT2 inhibitors—updated advice on diabetic ketoacidosis
10.How should levothyroxine fit around breakfast?
Food and caffeine-containing drinks can reduce levothyroxine absorption, making administration timing clinically relevant. NHS advice is to take it in the morning, ideally at least 30 minutes before breakfast or a caffeinated drink. Ask how the person actually takes the medicine before interpreting poor control as a need for more drug. A consistent, workable routine can address an administration problem without immediately changing a dose that was selected for different absorption conditions.
Apply it
A patient takes levothyroxine with breakfast and coffee because this is easiest to remember. Explain the absorption issue and agree a morning routine that allows the recommended interval before food and caffeine, then communicate the change during follow-up.
Common pitfall: Escalating the dose without checking administration may obscure an avoidable absorption problem. Changing timing can alter exposure, so it should be communicated during subsequent review.
11.Why should oral iron trigger an administration-timing review?
Oral iron can reduce levothyroxine absorption, so identify the exact products and construct a timed schedule. The Eltroxin/Levothyroxine 100 microgram tablet SmPC specifies separating administration from oral iron by 4–5 hours. For this product, levothyroxine at 7 am, breakfast and coffee no earlier than 7:30 am, and iron at noon provide a five-hour medicine interval while retaining the food interval. Explain the written schedule and check understanding. Use the relevant product instructions rather than presenting this product's interval as universal.
Apply it
A person taking Eltroxin 100 microgram tablets plans to take newly purchased ferrous sulfate with the morning tablet. Explain the absorption interaction and agree the 7 am levothyroxine and noon iron schedule, checking that other doses and interactions also fit.
Common pitfall: Saying only 'take separately' leaves the interval unresolved. Moving iron to breakfast would still fail to provide this product's documented 4–5-hour separation.
Eltroxin/Levothyroxine 100mcg tablets - Summary of Product Characteristics (SmPC) - (emc) | 435 · NHS: Taking ferrous sulfate with other medicines and herbal supplements · NHS: Levothyroxine
12.When is diarrhoea during amoxicillin treatment a warning sign?
Mild diarrhoea can occur with amoxicillin, but severe diarrhoea or diarrhoea containing blood or mucus requires stopping amoxicillin and calling a doctor or NHS 111 now. Ask about severity, blood, mucus, abdominal symptoms and general condition. The immediate medicine action belongs alongside urgent assessment; advice to seek help while continuing treatment is incomplete. Serious bowel symptoms may also occur after treatment, so a recently completed course remains relevant to the assessment and handover.
Apply it
A person taking amoxicillin reports frequent diarrhoea with visible blood. Tell them to stop amoxicillin and call a doctor or NHS 111 now. Communicate the antibiotic exposure and symptoms rather than offering symptomatic treatment as the complete response.
Common pitfall: Explaining that antibiotics commonly cause diarrhoea misses the decisive warning features. Do not advise finishing the course before seeking help when diarrhoea is severe or contains blood or mucus.
13.When does swallowing difficulty require urgent review?
Dysphagia means difficulty swallowing and may present as food sticking, coughing or choking with meals, regurgitation or a wet-sounding voice after swallowing. These features require assessment because swallowing difficulty can compromise nutrition and safe administration. NHS guidance advises urgent help for swallowing problems. Distinguish a request for symptom relief from evidence that swallowing itself is impaired; changing an over-the-counter product does not resolve the need to investigate the underlying problem.
Apply it
An adult asks for heartburn treatment but describes food repeatedly sticking and coughing when drinking. Identify possible dysphagia and arrange urgent clinical review instead of assuming uncomplicated reflux and managing the complaint entirely through a medicine sale.
Common pitfall: Calling food sticking ordinary indigestion can delay investigation. Recommending smaller tablets may address one inconvenience while leaving the underlying swallowing problem and its risks unassessed.
14.Why does frequent SABA use need an asthma review?
Review and adjust asthma treatment when as-needed SABA is used more than twice weekly. The MHRA requires urgent review when reliever prescription requests increase or prescribed anti-inflammatory maintenance treatment is not collected. Check symptoms, adherence and inhaler technique. Increased supply requests can signal risk even when the person is comfortable during consultation. Distinguish this urgent treatment review from worsening asthma symptoms that are unrelieved by prescribed reliever treatment: those require urgent medical assistance.
Apply it
A person requests salbutamol earlier than expected and has not collected prescribed corticosteroid treatment. Assess current symptoms and arrange urgent asthma review. If worsening symptoms are not relieved by the prescribed attack treatment, obtain urgent medical assistance.
Common pitfall: Temporary bronchodilation does not establish adequate control. A routine future review understates increased reliever requests, while an acute attack requires assistance beyond a treatment-review appointment.
MHRA: SABA overuse and changes in asthma prescribing guidance
15.What distinguishes asthma symptom relief from anti-inflammatory treatment?
A SABA relieves bronchoconstriction but does not provide the inhaled corticosteroid treatment needed to address airway inflammation. The MHRA update highlights corticosteroid-containing treatment and changes away from SABA-only management. Counselling should explain why symptom relief and control of inflammation are different treatment goals. Identify the person's actual inhalers and prescribed regimen, because the role of an inhaler depends on its ingredients and instructions rather than its colour or the patient's informal name.
Apply it
A person says they stopped their corticosteroid inhaler because salbutamol works faster. Explain the different treatment roles, check the prescribed regimen and arrange review so that rapid relief is not mistaken for adequate anti-inflammatory asthma treatment.
Common pitfall: Describing one inhaler as stronger without explaining its role encourages substitution. Inhaler colour alone is an unreliable way to identify ingredients or current treatment instructions.
MHRA: SABA overuse and changes in asthma prescribing guidance
16.How can weekly methotrexate instructions prevent fatal error?
Methotrexate for autoimmune diseases is generally taken once weekly, and accidental daily administration can cause fatal overdose. The key safety check is the intended indication and frequency, followed by a clearly agreed weekly day. Counselling should verify what the patient will actually do, not merely whether they recognise the medicine. A daily instruction for an autoimmune indication is a discrepancy requiring resolution before supply; do not extrapolate this weekly rule to all oncology regimens.
Apply it
A patient starting methotrexate for rheumatoid arthritis believes it belongs with their daily morning tablets. Establish the prescribed weekly day, demonstrate the schedule and ask the patient to describe it back before the first dose is taken.
Common pitfall: Assuming familiarity with daily medicines makes methotrexate easy to explain misses the central hazard. The once-weekly autoimmune regimen must be distinguished from specialist oncology schedules.
17.When should infection symptoms during chemotherapy prompt immediate contact?
Chemotherapy can reduce the body's ability to fight infection, making fever or other infection symptoms potentially urgent. Patients should use the immediate-contact advice and emergency number provided by their cancer team rather than waiting for a routine appointment. Ask about their treatment and the team's specific instructions, including temperature limits. A patient who feels suddenly unwell may need immediate advice even without an impressive temperature reading; the treatment context changes the significance of otherwise familiar symptoms.
Apply it
A patient receiving chemotherapy phones about shivering and feeling acutely unwell. Direct them to contact their cancer team's emergency service immediately using their treatment instructions, rather than advising them to wait overnight or first try routine cold remedies.
Common pitfall: Treating fever during chemotherapy like an uncomplicated viral illness can delay urgent care. Waiting for a particular temperature without considering the team's instructions is also unsafe.
18.Why does topical corticosteroid percentage not establish potency?
Hydrocortisone 1% is a mild topical corticosteroid, whereas betamethasone valerate 0.1% is potent. Percentage describes concentration; the corticosteroid molecule and formulation affect the preparation's potency and delivery. Compare recognised potency classes for the exact products. Body site and duration also matter: mild or moderate preparations are generally used on the face and folds, while stronger treatment may be prescribed there for specific conditions for short periods. Follow the prescribed site and course rather than substituting according to percentage.
Apply it
A patient thinks betamethasone valerate 0.1% is weaker than hydrocortisone 1% and plans to use it on the face for longer. Explain the mild-versus-potent comparison and check the prescribed body site and duration before use.
Common pitfall: A smaller printed percentage can belong to a more potent corticosteroid. Products prescribed for different sites or durations are not interchangeable on the basis of concentration.
19.Which red-eye features require emergency assessment?
A red eye accompanied by visual change or pain on looking at light needs emergency assessment under NHS advice. These features distinguish potentially serious eye disease from a simple request for soothing drops. Ask directly about vision and light sensitivity rather than relying on how red the eye looks. The immediate decision concerns safe referral; a pharmacist does not need to establish a definitive ophthalmic diagnosis before recognising these emergency features and acting on them.
Apply it
A person requests drops for a red eye and then mentions blurred vision and discomfort in bright light. Arrange emergency assessment rather than beginning an over-the-counter treatment trial and asking them to return if it fails.
Common pitfall: Assuming redness means conjunctivitis overlooks the importance of visual change and photophobia. Mild-looking redness does not reliably exclude a serious cause when these symptoms are present.
20.When is hearing loss too urgent for a wax-treatment trial?
Sudden hearing loss in one or both ears requires urgent medical assessment. The speed of onset is a critical discriminator because a patient may describe the sensation as blockage even when wax has not been established. Ask when the change began, whether it is worsening and whether associated symptoms are present. Do not allow an unconfirmed explanation such as wax to replace urgent assessment of a new sudden change in hearing.
Apply it
A person woke with markedly reduced hearing in one ear and asks for wax drops. Recognise the sudden onset and arrange urgent medical assessment rather than recommending several days of wax treatment before considering another explanation.
Common pitfall: The patient's description of a blocked ear does not confirm wax. A routine treatment trial may delay assessment when sudden onset is the important clinical cue.
21.When should folic acid be started, and who needs a higher dose?
For usual-risk pregnancies, take folic acid 400 micrograms daily before pregnancy and through the first 12 weeks. If already pregnant without supplementation, start promptly. Relevant higher-risk situations require prescribed folic acid 5 mg daily before pregnancy and through the first 12 weeks. Examples include a previous neural-tube-defect-affected pregnancy, a neural tube defect in either biological parent or their family, diabetes, or taking epilepsy or HIV medicines. Establish these factors when selecting advice.
Apply it
A person with diabetes is planning pregnancy. Explain that the higher-risk recommendation is prescribed folic acid 5 mg daily, rather than relying on the usual 400 microgram dose, and arrange the prescription before conception.
Common pitfall: Waiting for a positive test loses part of the intended preventive period. The routine dose should not be presented as sufficient for everyone with a qualifying higher-risk history.
22.Why does pregnancy change MMR vaccination advice?
MMR is a live vaccine and is not given during pregnancy. Establish pregnancy status when assessing vaccination suitability, and arrange an appropriate later vaccination plan when needed. NHS advice also includes avoiding pregnancy for one month after MMR vaccination. The decision is specific to this vaccine and situation; it does not mean that every vaccine is unsuitable during pregnancy. Explain the timing clearly so that deferral leads to a practical plan rather than permanent avoidance.
Apply it
A pregnant adult with uncertain MMR history asks to receive the vaccine today. Explain why MMR is deferred during pregnancy and help arrange follow-up after pregnancy rather than administering it or suggesting that all future vaccination is unsafe.
Common pitfall: Extending the live-vaccine precaution to all vaccines creates an inaccurate rule. Deferring MMR should include a clear opportunity to revisit protection at an appropriate time.
23.Why do fluid and sodium changes matter during lithium treatment?
Changes in fluid or sodium intake can affect lithium concentrations and toxicity risk. SPS advises maintaining adequate fluid intake and avoiding dietary changes that substantially increase or reduce sodium intake. Illness with vomiting or diarrhoea deserves particular attention because it can alter hydration while also resembling toxicity. Ask about recent illness and intake when evaluating new symptoms or an unexpected concentration, and ensure suspected toxicity receives urgent assessment rather than routine lifestyle counselling alone.
Apply it
A lithium-treated patient has had diarrhoea and has barely drunk for a day. Assess for toxicity symptoms and arrange appropriate urgent advice, explaining why reduced intake and fluid loss matter instead of treating hydration as an unrelated issue.
Common pitfall: Advising abrupt major salt restriction as generic healthy-living advice can be inappropriate during lithium treatment. Consistency and clinical review matter when intake or hydration changes substantially.
24.Which bleeding symptoms need attention during apixaban treatment?
Apixaban increases the likelihood of bleeding, but counselling must distinguish minor nuisance bleeding from warning signs requiring urgent help. Blood in urine, blood in vomit, black stools or bleeding that will not stop should not be dismissed as proof that treatment is working. Ask about the site, duration and severity of bleeding and any associated illness. Give clear action instructions while avoiding an unsupported self-directed change to the person's ongoing anticoagulant regimen.
Apply it
A patient taking apixaban reports black stools and asks whether bruising is simply expected with anticoagulation. Recognise the possible serious bleeding symptom and arrange urgent medical advice rather than grouping it with minor bruising and offering reassurance alone.
Common pitfall: Calling all bleeding an expected effect can conceal a serious event. Equally, routine counselling should not imply that every minor bruise requires permanent discontinuation of anticoagulation.
25.How should shared decisions address a patient's treatment concerns?
Person-centred care requires understanding what matters to the person and involving them in decisions about their care. A concern about adverse effects may reflect previous experience, practical barriers or different priorities rather than simple unwillingness. Explain relevant benefits and risks in understandable terms, explore the concern and agree a workable next step. Professional judgement remains necessary: involvement means an informed discussion, not either imposing a plan or accepting an unsafe misunderstanding without explanation.
Apply it
In a Great Britain pharmacy, a patient avoids a prescribed medicine after a relative experienced side effects. Explore the specific fear, explain the patient's own treatment context and agree how questions will be resolved with the prescriber.
Common pitfall: Repeating that the prescriber knows best does not address the concern. Agreeing uncritically with misinformation also fails to support an informed, person-centred treatment decision.
26.How can a pharmacist check that an explanation was understood?
Effective communication requires more than delivering accurate information; the pharmacist should check that the person can use it. Invite them to describe the plan in their own words or demonstrate the relevant task, framing this as a check on the explanation. This approach exposes misunderstandings about timing, dose or urgent symptoms that a yes-or-no question may miss. Adapt the explanation to the person's needs and repeat the check when a material misunderstanding is corrected.
Apply it
After explaining weekly methotrexate in a Great Britain pharmacy, ask the patient which day they will take it and what they will do on other days. Use their response to identify and correct any remaining daily-dosing misunderstanding.
Common pitfall: Asking only whether everything is clear often produces agreement without demonstrating understanding. The check should support the person rather than feel like an examination of them.
GPhC Standards for pharmacy professionals, May 2017 · MHRA: Methotrexate once-weekly for autoimmune diseases
27.What makes consent an ongoing communication process?
Consent involves the person's agreement to care following an explanation they can understand. It should relate to the proposed activity and remain open to questions or withdrawal rather than being reduced to obtaining a signature. Explain what is being offered and why, check understanding and respect the person's choices within the relevant professional and legal framework. If the proposed activity changes materially, revisit the discussion instead of assuming earlier agreement automatically covers the new intervention.
Apply it
In a Great Britain pharmacy, someone agrees to discuss a medicine but appears surprised when an additional service is proposed. Explain the separate activity and seek their agreement before proceeding rather than treating their attendance as blanket consent.
Common pitfall: Attendance, silence or possession of a signed form does not by itself establish understanding of every proposed activity. Consent must connect to the care actually being offered.
28.How should privacy shape a medicine consultation?
Respecting confidentiality includes how a conversation is conducted, not only whether a record is formally disclosed. Sensitive medicine information can be exposed through audible questions, visible paperwork or discussion with an unverified companion. Offer an appropriate private setting and establish whom the patient wants involved. In Great Britain, the GPhC standards require respect for privacy and confidentiality; practical communication should allow necessary care while limiting avoidable exposure of personal information to other customers or visitors.
Apply it
A patient begins discussing a sensitive medicine at a crowded Great Britain pharmacy counter. Offer a private consultation space and ask whether they want their companion involved before exploring details that other customers could otherwise overhear.
Common pitfall: Assuming confidentiality is satisfied because no electronic record was shared overlooks spoken disclosure. A companion's presence does not automatically establish permission to discuss every sensitive detail.
29.What information makes a clinical handover actionable?
A useful handover explains the current concern, relevant medicine exposure, important findings and the action required. Separate what the patient reported from what was observed or confirmed, and state any immediate steps already taken. The receiving professional should understand why the case needs attention and how urgently. Collaborative care also requires communicating relevant information appropriately and checking that responsibility for the next action is clear, rather than assuming that leaving a message completes the referral.
Apply it
When referring possible lithium toxicity, communicate the symptoms, recent illness, lithium regimen, available dose timings and action already taken. State that urgent assessment is required and confirm how the patient will reach the receiving service.
Common pitfall: Sending a long medicine list without explaining the immediate concern obscures urgency. A referral is incomplete if nobody understands who will perform the next necessary action.
GPhC Standards for pharmacy professionals, May 2017 · NHS SPS: Lithium monitoring
30.How should communication adapt to an individual's needs?
Effective communication depends on the individual rather than a standard script. Establish preferred language, hearing or visual needs, health understanding and the practical circumstances affecting medicine use. Use an appropriate communication method and check comprehension without making assumptions from age, appearance or diagnosis. In Great Britain, the GPhC standards link person-centred care with effective communication and respect. Adaptation should preserve the accuracy and completeness of the decision while making it accessible to the particular person.
Apply it
An older patient in a Great Britain pharmacy struggles to hear instructions in a noisy area. Move to a suitable space, ask how they prefer information presented and check their understanding rather than simply speaking faster or addressing a companion.
Common pitfall: Giving everyone the same leaflet does not establish equal understanding. Speaking only to a companion can exclude the patient when direct, adapted communication remains possible.
Professional practicenot stated
31.How is percentage weight-in-volume converted to a usable concentration?
A percentage weight-in-volume concentration states grams of solute in each 100 mL of final preparation. Convert this into the units needed before calculating a dose or quantity. For example, 2% w/v means 2 g in 100 mL, equivalent to 20 mg/mL. The denominator describes final preparation volume, not necessarily the volume of solvent initially added. Writing the relationship explicitly prevents confusion between percentage values and milligrams per millilitre during subsequent multistep calculations.
Apply it
A hypothetical 1.5% w/v preparation is required in a 200 mL final volume. Interpret this as 1.5 g per 100 mL, so 3 g of solute is needed, with the preparation made up to 200 mL.
Common pitfall: Reading 1.5% w/v as 1.5 mg/mL introduces a tenfold error. Adding solute to the entire stated solvent volume may also misinterpret the required final volume.
Common Registration Assessment framework: For sittings in 2026
32.How does percentage weight-in-weight guide ingredient quantities?
Percentage weight-in-weight expresses grams of an ingredient in each 100 g of final product. Calculate the ingredient mass from the required final mass, then determine the remaining base mass if the exercise assumes additive masses. A 4% w/w product contains 4 g per 100 g, regardless of its volume. Keep mass and volume distinct: converting between them requires density information when the question does not otherwise define an appropriate relationship for the preparation.
Apply it
An exercise requires 75 g of a 4% w/w mixture from pure ingredient and base. Calculate 3 g of ingredient and, assuming no losses and additive masses, 72 g of base to achieve the required final mass.
Common pitfall: Using 75 mL instead of 75 g assumes an unsupported density. Adding 3 g to 75 g of base produces the wrong final mass and concentration.
Common Registration Assessment framework: For sittings in 2026
33.What does percentage volume-in-volume specify?
Percentage volume-in-volume gives the volume of a liquid ingredient in each 100 units of final preparation volume. A 10% v/v preparation therefore contains 10 mL of ingredient in 100 mL of final product. The instruction usually requires making up to the final volume rather than assuming all component volumes add exactly. Identify whether the question asks for ingredient volume, final volume or diluent volume before selecting the relevant relationship and calculation steps.
Apply it
A hypothetical preparation requires 250 mL at 8% v/v using a pure liquid ingredient. Calculate 20 mL of ingredient, then make up to the specified final volume according to the stated preparation assumptions and instructions.
Common pitfall: Treating 8% as 8 mL in every container ignores final volume. Subtracting component volumes is justified only when the exercise permits the necessary volume-additivity assumption.
Common Registration Assessment framework: For sittings in 2026
34.Why does dilution conserve the amount of solute?
When only diluent is added and no solute is lost, the total amount of solute stays constant while concentration falls. This supports C1V1 = C2V2 when concentrations use compatible units and volumes describe the corresponding solutions. First calculate the stock volume containing the required amount, then make up to the target final volume. Distinguish the required final volume from the additional diluent volume, and check that the proposed dilution actually lowers the concentration.
Apply it
To prepare 200 mL of a hypothetical 2 mg/mL solution from 10 mg/mL stock, calculate 40 mL of stock. Make this up to 200 mL; under additive-volume assumptions, this requires 160 mL of diluent.
Common pitfall: Adding 200 mL of diluent to 40 mL of stock produces 240 mL and the wrong concentration. The target volume is the final preparation volume.
Common Registration Assessment framework: For sittings in 2026
35.How should two strengths be combined to reach a target concentration?
Combining solutions requires accounting for the solute contributed by each component. Under an additive-volume assumption, total solute equals the first concentration multiplied by its volume plus the second concentration multiplied by its volume. Divide by final volume to find the mixture concentration, or solve the equation for an unknown component volume. A target between the two starting concentrations is feasible by mixing them; a target outside their range requires another operation or ingredient.
Apply it
An exercise asks for 100 mL at 6 mg/mL from 10 mg/mL and 2 mg/mL solutions, assuming additive volumes. Equal 50 mL portions contribute 500 mg and 100 mg, producing 600 mg in 100 mL.
Common pitfall: A simple average of concentrations works only for equal component volumes. Always weight each concentration by its contribution rather than averaging labels regardless of quantity.
Common Registration Assessment framework: For sittings in 2026
36.How does displacement volume change reconstitution arithmetic?
A dissolved powder can contribute to final solution volume, so the solvent added may be less than the desired final volume. Use the displacement information provided to calculate that contribution. Under the exercise's stated model, solvent volume equals required final volume minus powder displacement. After reconstitution, use the resulting final concentration to calculate a withdrawal volume. Keep these two stages separate: calculating solvent to add and calculating solution to withdraw answer different questions.
Apply it
A hypothetical 1 g powder displaces 0.8 mL and must yield 10 mL of final solution. Add 9.2 mL solvent under the stated model. The resulting 100 mg/mL concentration means a 250 mg portion occupies 2.5 mL.
Common pitfall: Adding the full desired final volume as solvent ignores powder displacement. Using solvent volume as the concentration denominator then creates a second, related calculation error.
Common Registration Assessment framework: For sittings in 2026
37.How do mg/kg/day and mg/kg/dose differ?
A dose expressed in mg/kg/day specifies the total amount across a day, while mg/kg/dose specifies the amount at each administration. For a daily expression, multiply by body weight and then divide by the stated number of doses. For a per-dose expression, multiply by weight without that daily division. Only then convert milligrams into tablets or millilitres. The wording of the regimen determines the calculation; the numerical dose rate alone is insufficient to choose an operation.
Apply it
A hypothetical exercise specifies 24 mg/kg/day in three equal doses for a 20 kg patient. Calculate 480 mg daily and 160 mg per dose, then use the supplied product concentration to calculate the administration volume.
Common pitfall: Giving the calculated daily total at every administration multiplies exposure by the dosing frequency. Underlining whether the expression says per day or per dose prevents this error.
Common Registration Assessment framework: For sittings in 2026
38.How should a changing regimen be translated into total quantity?
A regimen that changes over time should be divided into phases, with each phase calculated separately. Multiply units per administration by administrations per day and days in that phase, then add the phase totals. Confirm whether the available strength permits the stated dose and whether splitting is allowed within the exercise. This method makes transitions visible and avoids applying the first or final dose to the whole course when calculating the quantity to supply.
Apply it
A hypothetical course uses three tablets daily for four days, then two daily for three days, then one daily for two days. Calculate 12, 6 and 2 tablets respectively, giving a total requirement of 20 tablets.
Common pitfall: Multiplying the starting daily quantity by the full course length overestimates supply. Using only the final daily quantity underestimates it and hides the regimen's changing phases.
Common Registration Assessment framework: For sittings in 2026
39.When must a calculated tablet or pack quantity be rounded upward?
Rounding depends on what the calculated number represents. If only whole packs can be supplied and the exercise requires enough medicine for the entire course, round the required pack count upward. Do not transfer that rule to a clinical dose, where rounding upward may increase exposure inappropriately. Establish the supply constraint explicitly, calculate the unrounded requirement and apply the rule at the correct stage. The final answer must be practical without silently changing the prescribed regimen.
Apply it
An exercise requires 31 tablets, available only in sealed packs of 14 with no splitting permitted. Calculate 31 divided by 14, then round upward to three packs, providing enough tablets under the stated supply constraint.
Common pitfall: Rounding 2.21 packs down to two leaves insufficient supply. Conversely, rounding every intermediate dose upward is not justified by a whole-pack supply rule.
Common Registration Assessment framework: For sittings in 2026
40.How is a liquid course converted into bottles to supply?
Calculate the volume at each administration, multiply by daily frequency and course length, and then apply the stated bottle-size or dispensing constraint. Check whether the concentration is given per millilitre or per five millilitres before converting the dose. The required treatment volume and the supplied bottle volume are related but different answers. State which one the question requests, and consider any explicitly supplied stability or wastage assumptions without inventing extra quantities or extensions.
Apply it
A hypothetical liquid course uses 7.5 mL three times daily for seven days. The treatment volume is 157.5 mL. If only whole 100 mL bottles may be supplied, the exercise requires two bottles rather than one.
Common pitfall: Confusing milligrams per 5 mL with milligrams per millilitre causes a fivefold conversion error. Reporting treatment volume also fails when the requested answer is whole bottles.
Common Registration Assessment framework: For sittings in 2026
41.How is a prescribed infusion duration converted to mL/hour?
For a fixed-volume infusion, the volumetric rate equals the volume to be administered divided by the duration in hours. Convert minutes into hours before dividing, and distinguish the volume actually prescribed for administration from any larger stock container. A useful check is to multiply the resulting rate by the stated duration and recover the intended volume. This dimensional approach helps identify an answer accidentally expressed in millilitres per minute instead of millilitres per hour.
Apply it
A hypothetical infusion requires 180 mL over 90 minutes. Convert 90 minutes to 1.5 hours, then calculate 180 divided by 1.5, giving 120 mL/hour. Check that this rate delivers 180 mL over the specified period.
Common pitfall: Dividing by 90 and labelling the result mL/hour omits the time conversion. A plausible-looking small number can still carry the wrong time unit.
Common Registration Assessment framework: For sittings in 2026
42.How does solution concentration convert a dose rate into a pump rate?
A prescribed mass per hour becomes a volume per hour by dividing by the solution concentration in mass per millilitre. First calculate that concentration from the total drug amount and final infusion volume. Keep mass units consistent before dividing. The reverse check multiplies pump rate by concentration to recover the prescribed mass rate. This separates a clinical dose instruction from the device setting and makes it easier to detect an answer based on stock strength.
Apply it
An exercise states that 240 mg is made up to 120 mL and must deliver 12 mg/hour. The concentration is 2 mg/mL, so the pump rate is 6 mL/hour. Multiplication confirms delivery of 12 mg each hour.
Common pitfall: Dividing by the total milligrams in the bag rather than milligrams per millilitre gives the wrong dimension. Use the final prepared concentration, not an undiluted stock label.
Common Registration Assessment framework: For sittings in 2026
43.How can micrograms/kg/minute be converted safely to mL/hour?
A weight-based infusion expressed per minute requires several explicit conversions. Multiply the dose rate by body weight to obtain micrograms per minute, multiply by 60 for micrograms per hour, and convert to the mass unit used by the prepared concentration. Divide by that concentration to obtain millilitres per hour. Carrying units through each step exposes missing factors of 60 or 1,000 and prevents a numerical answer from appearing correct despite an incompatible dimension.
Apply it
A hypothetical exercise specifies 2 micrograms/kg/minute for 50 kg using 1 mg/mL solution. This is 100 micrograms/minute, 6,000 micrograms/hour or 6 mg/hour, requiring 6 mL/hour. The calculation supplies no treatment recommendation.
Common pitfall: Converting the microgram unit but forgetting minutes-to-hours leaves a sixtyfold error. Converting time but not micrograms-to-milligrams can introduce a thousandfold error instead.
Common Registration Assessment framework: For sittings in 2026
44.How are absolute risk reduction and number needed to treat related?
Absolute risk reduction is the control event risk minus the treatment event risk for a specified outcome and follow-up period. Number needed to treat is its reciprocal when risks are expressed as proportions. State the outcome and duration because the number is not a timeless property of a medicine. For a whole-person interpretation, round the calculated NNT upward where appropriate. Distinguish percentage points from percentages before deciding which value belongs in the reciprocal calculation.
Apply it
In a hypothetical one-year study, an event occurs in 12% of controls and 8% of treated participants. The absolute reduction is four percentage points, or 0.04, giving an NNT of 25 over one year.
Common pitfall: Calculating one divided by four instead of one divided by 0.04 misuses percentage units. Reporting NNT without the outcome and follow-up period removes essential interpretation.
Common Registration Assessment framework: For sittings in 2026
45.Why can relative and absolute risk reductions tell different stories?
Relative risk compares treatment event risk with control event risk, while absolute risk reduction subtracts the two risks. Relative risk reduction is one minus relative risk. A large relative reduction may correspond to a small absolute benefit when the starting risk is low. Present both when interpreting a study or discussing benefit, and verify that groups concern the same outcome and follow-up period. Neither measure alone establishes whether the result applies to a different patient population.
Apply it
A hypothetical intervention reduces one-year event risk from 2% to 1%. The relative risk is 0.5 and relative reduction 50%, but the absolute reduction is one percentage point. Explain both rather than presenting only the larger percentage.
Common pitfall: Calling a 50% relative reduction a fifty-percentage-point improvement exaggerates benefit. Relative and absolute measures use different denominators and cannot be substituted without calculation.
Common Registration Assessment framework: For sittings in 2026
46.Which costs belong in a treatment-cost comparison?
A meaningful cost comparison uses the perspective, time horizon and cost categories specified in the exercise. Acquisition price alone may not represent total cost if administration, monitoring or other resources differ. Calculate each included component on a consistent per-patient or programme basis before comparing alternatives. Do not invent omitted costs or assume the cheaper product produces equivalent outcomes; the question must establish the relevant assumptions before a cost-minimisation conclusion can be justified for its stated purpose.
Apply it
An exercise states equal outcomes and asks for annual provider costs. Treatment A costs £100 plus £80 monitoring; treatment B costs £140 plus £20 monitoring. Their totals are £180 and £160, making B cheaper within the stated perspective.
Common pitfall: Choosing solely by medicine purchase price overlooks explicitly included monitoring costs. Mixing annual costs for one option with monthly costs for another creates an invalid comparison.
Common Registration Assessment framework: For sittings in 2026
47.How is an incremental cost-effectiveness ratio calculated?
An incremental cost-effectiveness ratio divides the difference in costs by the difference in outcomes between two options. Use a consistent direction for both subtractions and retain the outcome unit, such as cost per additional quality-adjusted life year. This measures additional cost for additional benefit, not total cost divided by total outcome for one option. Whether the result represents acceptable value requires a decision rule or context; the arithmetic alone does not supply a funding recommendation.
Apply it
A hypothetical option costs £300 more and yields 0.02 additional quality-adjusted life years per patient. Dividing £300 by 0.02 gives £15,000 per additional quality-adjusted life year, before applying any separately specified decision threshold.
Common pitfall: Dividing the newer option's total cost by its total outcome gives an average ratio. Incremental analysis requires differences between the specified alternatives in both numerator and denominator.
Common Registration Assessment framework: For sittings in 2026
48.How does half-life predict concentration decline in a simple model?
Under a stated first-order elimination model with no additional doses, concentration halves during each half-life. After n half-lives, the remaining fraction is one-half raised to n. Identify the elapsed number of half-lives before applying the relationship, and keep the model's assumptions explicit. This predicts a proportional decline rather than subtraction of the same concentration each interval. Real clinical interpretation may require information beyond this simplified exercise, including ongoing input or changing elimination conditions.
Apply it
An exercise specifies an initial concentration of 80 mg/L, a four-hour half-life and no further dosing under first-order elimination. After twelve hours, three half-lives have elapsed, leaving 10 mg/L rather than subtracting a fixed amount each hour.
Common pitfall: Subtracting half the initial concentration repeatedly eventually gives impossible negative values. First-order decline removes the same fraction, not the same absolute amount, during each half-life.
Common Registration Assessment framework: For sittings in 2026
49.How does clearance determine a modelled maintenance infusion rate?
When an exercise supplies the steady-state relationship, maintenance infusion rate equals target concentration multiplied by clearance. Concentration in mg/L and clearance in L/hour produce a rate in mg/hour. Convert this mass rate into a pump rate only after establishing the prepared concentration. This relationship concerns ongoing replacement of eliminated drug under the stated model; it does not calculate a loading dose or specify how rapidly the target concentration will initially be reached.
Apply it
A hypothetical model gives clearance of 3 L/hour and a target of 4 mg/L. The maintenance input is 12 mg/hour. If the exercise supplies a 2 mg/mL infusion, the corresponding pump rate is 6 mL/hour.
Common pitfall: Using volume of distribution instead of clearance confuses loading and maintenance relationships. Omitting units can conceal that the calculation produced a mass rate rather than a pump setting.
Common Registration Assessment framework: For sittings in 2026
50.How does bioavailability enter a modelled loading-dose calculation?
When the exercise supplies the relationship, loading dose equals target concentration multiplied by volume of distribution and divided by bioavailability. Bioavailability is entered as a fraction, so 50% becomes 0.5. The calculation estimates the administered amount needed to achieve the modelled target after accounting for the fraction reaching systemic circulation. It is distinct from maintenance dosing, which replaces ongoing elimination. Use only the route, assumptions and parameters specified rather than transferring the numerical result into clinical practice.
Apply it
A hypothetical formula gives a target of 2 mg/L, volume of distribution of 40 L and bioavailability of 0.5. The modelled loading dose is 160 mg because 80 mg systemically requires twice that administered amount.
Common pitfall: Multiplying by bioavailability instead of dividing makes the administered dose smaller when less drug reaches circulation. Entering 50 rather than 0.5 creates a separate percentage error.
Common Registration Assessment framework: For sittings in 2026
51.When should rounding occur in a multistep calculation?
Rounding should follow the requested precision and the practical constraints of the answer. Retain sufficient precision during intermediate calculations so that repeated early rounding does not distort the final result. Distinguish an exact mathematical result from an administrable dose, measurable volume or whole-pack quantity. Apply any supplied rounding instruction at its intended stage, and check whether the final unit and decimal places match the question. A calculator display is not itself a decision about appropriate reporting precision.
Apply it
A hypothetical calculation produces 1.276 mL and explicitly requests an answer to two decimal places. Report 1.28 mL after completing the calculation, rather than rounding an earlier concentration and obtaining a materially different final result.
Common pitfall: Rounding every intermediate value to one decimal place can accumulate error. Reporting every calculator digit also fails when the question specifies a practical precision or whole-unit constraint.
Common Registration Assessment framework: For sittings in 2026
52.Which exclusions and quantity limits govern patient-requested emergency supply in England?
Under the Human Medicines Regulations 2012, regulation 225, ordinary non-controlled POMs have a maximum of 30 days' treatment. Exceptions include the smallest available prepacked insulin, asthma aerosol, ointment or cream; one full oral-contraceptive treatment cycle; and the smallest quantity completing an oral liquid antibiotic course. Schedule 4 or 5 controlled drugs have a five-day limit. Schedule 1–3 controlled drugs are excluded apart from the phenobarbital/phenobarbital sodium exception for epilepsy. Schedule 18 substances, including piracetam, are excluded. These are limits and exclusions, not automatic authority to supply: the interview, previous prescribing, immediate need, appropriate dose, records and label must also satisfy the law. See [regulation 225](https://www.legislation.gov.uk/uksi/2012/1916/regulation/225/data.html), [regulation 213](https://www.legislation.gov.uk/uksi/2012/1916/regulation/213/data.html) and [Schedule 18](https://www.legislation.gov.uk/uksi/2012/1916/schedules/data.html).
Apply it
An established patient requests 56 days of a non-controlled maintenance tablet during an emergency. Even if the other conditions are met, that quantity exceeds the ordinary 30-day limit. Select a justified quantity within the limit and arrange ongoing access.
Common pitfall: A usual repeat quantity does not override the emergency-supply limit. Conversely, the smallest-pack exception must not be applied to every POM.
Common Registration Assessment framework: For sittings in 2026
53.When is suspicion sufficient for a Yellow Card report?
Healthcare professionals should report all serious suspected adverse reactions to established medicines and vaccines, including recognised reactions. For black-triangle products, report all suspected adverse reactions, whether serious or non-serious. Suspicion is sufficient: proven causality is not required. Record useful medicine, reaction and timing information while addressing urgent patient care separately. Reporting supports assessment of safety signals; it does not prove that the medicine caused the individual event.
Apply it
A patient is admitted to hospital with a recognised reaction suspected to involve an established medicine. Report the serious suspected reaction even though it is already listed in the product information and another cause remains possible.
Common pitfall: Restricting established-medicine reports to previously unknown reactions misses serious recognised reactions. Waiting for definitive causality can also suppress useful safety information.
54.What does the black triangle mean for medicine safety reporting?
A black triangle identifies a medicine under additional monitoring and signals that all suspected adverse reactions should be reported through the Yellow Card scheme. It does not mean that the medicine is necessarily unsafe or that every reported event has been confirmed as caused by it. The practical consequence is a lower reporting threshold, including suspected reactions that may already be recognised. Explain the symbol accurately so that enhanced surveillance supports informed use rather than unnecessary alarm.
Apply it
A patient notices a black triangle beside a medicine name and fears it means the product has been banned. Explain additional monitoring and the request to report suspected reactions, while addressing any symptoms and the person's treatment concerns.
Common pitfall: Interpreting the symbol as proof of unusual danger misrepresents its purpose. Restricting reports to unexpected reactions also misses the broader reporting expectation for these medicines.
55.How should professional candour guide the response to an error?
When care goes wrong, professional candour requires openness and honesty with the affected person. In Great Britain, the GPhC standards require explaining what happened, apologising and taking action to put matters right where possible. First establish and address any immediate risk, then communicate known facts without speculation or concealment. Accurate records and learning should support prevention of recurrence. An internal investigation can refine understanding, but it should not become a reason to leave the patient uninformed about a known error.
Apply it
A Great Britain pharmacist confirms that a patient received the wrong strength. Assess possible harm promptly, explain the confirmed error and apologise, arrange corrective care and document events rather than waiting for a management meeting before contacting the patient.
Common pitfall: Replacing the medicine silently may correct the supply but fails to address the person's need for information. Avoid guessing about consequences that have not yet been assessed.
56.When should a pharmacy safety concern be raised?
A concern should be raised when conduct, systems or working conditions may put people at risk. The GPhC standards require speaking up and taking appropriate action, including when doing so is uncomfortable. Describe the observed problem, its potential consequences and any immediate protective steps rather than relying on accusations or vague dissatisfaction. Escalate appropriately if the concern remains unresolved. A near miss can reveal a hazardous process even when no patient has yet experienced harm from it.
Apply it
In a Great Britain pharmacy, repeated interruptions lead to several selection near misses. Record concrete examples, raise the patient-safety concern with the responsible person and seek practical controls rather than waiting until an incorrect medicine reaches a patient.
Common pitfall: No harm yet does not establish a safe system. Raising a concern once also does not complete the responsibility if a serious unresolved risk continues.
57.How should competence limits affect a clinical decision?
Professional judgement includes recognising the limits of one's knowledge and skills and obtaining appropriate help. The safe response is to identify the precise uncertainty, gather relevant information and involve someone competent to resolve it while protecting the patient from avoidable delay or error. In Great Britain, GPhC standards require maintaining knowledge and skills and using professional judgement. Confidence or familiarity with a medicine name does not establish competence to make every formulation, monitoring or treatment decision involving it.
Apply it
A Great Britain pharmacist is asked to convert an unfamiliar Parkinson's regimen after swallowing deteriorates. Identify the exact products and timing needs, consult suitable specialist guidance or expertise and communicate a clear interim plan that avoids unreviewed manipulation or omission.
Common pitfall: Guessing to appear decisive can create harm. Equally, stating that the problem is outside one's competence without arranging appropriate help leaves the patient's need unresolved.
GPhC Standards for pharmacy professionals, May 2017 · NHS SPS: Parkinson's disease medicines in swallowing difficulties
58.When can an English pharmacist make an emergency supply at a patient's request?
The Human Medicines Regulations 2012, regulation 225, requires the pharmacist to interview the requester and establish immediate need, impracticability of obtaining a prescription without undue delay, previous prescribing by a relevant prescriber, and an appropriate dose. The medicine must be eligible, its quantity within the applicable limit, and recording and labelling requirements met. A previous supply alone does not establish every condition. This patient-request route does not require a prescriber's promise to provide a prescription within 72 hours; that belongs to the separate prescriber-request route. See [regulation 225](https://www.legislation.gov.uk/uksi/2012/1916/regulation/225/data.html).
Apply it
In England, an adult has run out of amlodipine 5 mg daily. Records confirm previous prescribing by their UK GP; interview confirms immediate need, an appropriate unchanged dose and inability to obtain a prescription without undue delay. A justified seven-day supply can meet the patient-request route when the remaining legal requirements are completed.
Common pitfall: An empty pack supports identification but does not replace the interview. Clinical suitability and statutory authority must both be established.
Common Registration Assessment framework: For sittings in 2026
59.How should conflicting medicine information be reconciled?
Conflicting lists require clarification of what the person is actually taking and what the current intended regimen is. Compare relevant records with the patient's account, identify the exact discrepancy and confirm it with an appropriate source before relying on either list. Record the resolution and communicate material changes to those providing care. This applies professional judgement and collaborative care: copying the newest-looking document without checking can perpetuate an error, particularly when timing or frequency is clinically important.
Apply it
A hospital list and a patient's account show different Parkinson's medicine times. Establish the actual pre-admission regimen, clarify the intended current plan with the care team and communicate the reconciled schedule to the people administering the medicines.
Common pitfall: The most recent document may repeat an earlier transcription error. Reconciliation requires resolving the discrepancy, not merely choosing whichever source is easiest to access.
GPhC Standards for pharmacy professionals, May 2017 · NHS SPS: Parkinson's disease medicines in swallowing difficulties
60.Which records and label complete a patient-requested emergency supply in England?
Record the supply date, medicine name, quantity, form and strength where not apparent, patient's name and address, and nature of the emergency. Make the entry on the supply day or, if not reasonably practicable, the following day; retain the record for two years from its last entry. The emergency label must show supply date, medicine name, quantity and strength where not apparent, requester name, pharmacy name and address, and 'Emergency Supply'. Include appropriate administration directions and precautions. See [regulation 253](https://www.legislation.gov.uk/uksi/2012/1916/regulation/253/data.html), [Schedule 23](https://www.legislation.gov.uk/uksi/2012/1916/schedule/23/data.html), [regulation 225](https://www.legislation.gov.uk/uksi/2012/1916/regulation/225/data.html) and [Schedule 26](https://www.legislation.gov.uk/uksi/2012/1916/schedules/data.html).
Apply it
For seven amlodipine 5 mg tablets supplied after the required interview, record the patient's address and why a prescription could not be obtained in time. Label the actual quantity, confirmed daily instructions and required particulars, including 'Emergency Supply'.
Common pitfall: An ordinary dispensing label without the emergency wording is incomplete. A stock decrement or a note saying only 'ran out' does not supply all statutory record particulars.
Common Registration Assessment framework: For sittings in 2026
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Give cardiovascular decisions extra attention because this is the most frequently assessed clinical area, without assigning an invented percentage.
- Practise red-flag discrimination across all fifteen clinical areas, including eye, hearing, swallowing, pregnancy, vaccines and drug toxicity.
- Link high-risk medicines to their characteristic failure modes: anticoagulant bleeding, lithium toxicity, weekly methotrexate errors and delayed Parkinson's doses.
- Cover all nine guaranteed Part 1 calculation categories, carrying units through each step and checking final-volume, daily-dose and rounding assumptions.
- Integrate communication, confidentiality, candour and professional judgement with the statutory conditions, exclusions, quantity limits, records and labelling for lawful supply.
- Use the complete 2026 official framework to identify remaining gaps beyond these selective concepts, including the full high-risk medicine list and current safety alerts.
A practical preparation plan
1. Map the full scope
Build a study map from the 2026 official framework covering both domains, all fifteen clinical areas and all nine calculation categories. Mark these 60 concepts as selected foundations, then add topics not developed here.
2. Learn the decisive cues
For each clinical topic, state the finding that changes management: blood in antibiotic-associated diarrhoea, visual change with red eye, sudden hearing loss or neurological symptoms during lithium treatment.
3. Work calculations from units
Write what is given, what is requested and the conversion path. Practise numerical-entry working as well as these multiple-choice drills. Separate dose, concentration, final volume and quantity-to-supply calculations.
4. Explain the action aloud
Practise concise patient explanations and professional handovers. Include why the concern matters, what should happen next, how urgently it should happen and how understanding will be checked.
5. Review every alternative
Complete the 20 questions independently, then explain why each alternative is less appropriate. Record the mistaken assumption behind an error and revisit the relevant concept and clinical reference.
6. Rehearse both assessment parts
Progress to practice reflecting the official numerical-entry, five-option SBA and eight-option EMQ formats. Use official timing information in the FAQs, practise supplied-resource interpretation and review current MHRA safety advice.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- Common Registration Assessment framework: For sittings in 2026
- Common Registration Assessment regulations for sittings in 2026
- Common Registration Assessment specification and permitted items for sittings in 2026
- GPhC Standards for pharmacy professionals, May 2017
- NHS SPS: Managing interactions with direct oral anticoagulants
- NHS: Apixaban
- NHS: High blood pressure
- NHS SPS: Lithium monitoring
- NHS SPS: Parkinson's disease medicines in swallowing difficulties
- MHRA: SGLT2 inhibitors—updated advice on diabetic ketoacidosis
- NHS: Taking ferrous sulfate with other medicines and herbal supplements
- NHS: Levothyroxine
- NHS: Side effects of amoxicillin
- NHS: Dysphagia
- MHRA: SABA overuse and changes in asthma prescribing guidance
- MHRA: Methotrexate once-weekly for autoimmune diseases
- NHS: Chemotherapy
- NHS: Red eye
- MHRA: Yellow Card scheme guidance
- NHS: Pregnancy vitamins and supplements
- Guy's and St Thomas' NHS Foundation Trust: Topical steroids
- NHS: Hearing loss
- NHS: MMR vaccine
- How and when to take lithium - NHS
- Priadel 400 mg prolonged-release tablets - Summary of Product Characteristics (SmPC) - (emc) | 13163
- Eltroxin/Levothyroxine 100mcg tablets - Summary of Product Characteristics (SmPC) - (emc) | 435
- MMRVAXPRO Powder and solvent for suspension for injection in pre-filled syringe - Patient Information Leaflet (PIL) - (emc) | 6307
- Evidence-and-data-interpretation-in-the-AKT-Nov-2019-(1).pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.